Mild Hyperbaric Therapy and Hyperbaric Oxygen Therapy may easily be confused by the general public as being the same. Essentially the difference lies in the effective oxygen dose.

Oxygen is an extremely useful and efficacious drug in a wide range of medical conditions. Hyperbaric oxygen therapy (HBOT) is an established treatment for a number of health conditions. It is available at approximately 14 centres around Australia and New Zealand, including both Public hospitals and Private facilities.

The Undersea and Hyperbaric Medical Society (UHMS) is the peak world body representing practitioners in this area and defines Hyperbaric Oxygen Therapy as: ‘A treatment in which a patient breathes 100% oxygen while inside a treatment chamber at a pressure higher than sea level pressure (i.e. >1 atmosphere absolute or ATA)’.

These pressure vessels or chambers are typically operated at pressures above 202.6kPa (2 atmospheres absolute – ATA) for periods of 60 to 120 minutes for each session of treatment, with the patient breathing 100% oxygen.

Breathing 100% oxygen at 2.4 ATA, each breath taken contains oxygen at a pressure of 2.4 ATA (1,824 mmHg) and the arterial oxygen pressure will reach something around 2.0 ATA (1,500 mmHg).

Typically mild hyperbaric therapy or ‘low pressure hyperbaric therapy’ does not provide any more available oxygen to the body than oxygen administration at one atmosphere (sea level). It may be defined as ‘A treatment, usually administered in an inflatable portable chamber, in which a patient breathes air or oxygen enriched air at pressures between 1.2 and 1.5 ATA (slightly higher than sea level pressure).’

A typical mild Hyperbaric Therapy session will involve pressurisation to 1.3 ATA breathing 30% oxygen for about one hour. Under these conditions, each breath has an oxygen pressure of 0.4 ATA (296 mmHg) and the arterial pressure is likely to reach a more modest 0.3 ATA (230 mmHg). This is the same oxygen pressure that can be attained by breathing about 35% oxygen at sea level. To put it another way – this amount of oxygen can easily be achieved without the use of the chamber at all.

The ANZHMG (Australian and New Zealand Hyperbaric Medicine Group) is not aware of any reliable clinical evidence for therapeutic benefit from mild hyperbaric therapy and does not recommend the use of this modality for any medical purpose.

 

  1. Bennett MH. The evidence basis of diving and hyperbaric medicine. Mauritius: VDM Verlag 2008.
  2. Collet JP, Vanasse M, Marois P, Amar M, Goldberg J, Lambert J, et al. Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial. HBO-CP Research Group.[see comment]. Lancet357(9256):582-6. 2001.
  3. Bennett M, Newton H. Hyperbaric oxygen therapy and cerebral palsy – where to now? Undersea & Hyperbaric Medicine. 2007;34(2):69-74.
  4. Rossignol DA, Rossignol LW, Smith S, Schneider C, Logerquist S, A. U, et al. Hyperbaric treatment for children with autism: a multicenter, randomised. double-blind, controlled trial. BMC Pediatrics. 2009;9:21.
  5. Bennett M. The treatment of autism spectrum disorder with hyperbaric oxygen therapy. In: UHMS, editor. UHMS Position Paper. Durham: NC; 2010.
  6. Bennett MH, Trytko BE, Jonker B. Hyperbaric oxygen therapy for the adjunctive treatment of traumatic brain injury. (Cochrane Review). John Wiley & Sons, Ltd 2004.
  7. Bennett M, Heard R. Hyperbaric oxygen therapy for multiple sclerosis. Cochrane Database SystRev. 2004(1):CD003057.
  8. Bennett MH, Wasiak J, Schnabel A, Kranke P, French C. Hyperbaric oxygen therapy for acute ischaemic stroke. John Wiley and Sons Ltd; 2005; Issue 3
  9. Bennett M, French C, Schnabel A, Wasiak J, Kranke P. Normobaric and hyperbaric oxygen for migraine and cluster headache. Cochrane Database Syst Rev. 2008;Issue 3:CD005219.pub2.
  10. Bennett MH, Best TM, Babul S, Taunton JB. Hyperbaric oxygen therapy for delayed onset muscle soreness and closed soft tissue injury. 2005; Art. No.: CD004713. DOI: 10.1002/14651858.CD004713.pub2].
  11. Bennett MH, Smee R, Milross C, Feldmeier J. Hyperbaric oxygen therapy for tumour sensitization to radiation therapy (Cochrane Review). The Cochrane Library 2005;4(CD005007)
    .

Get in touch to see how our team can help you

Contact Us